| Literature DB >> 15310404 |
Ping Jin1, Yingdong Zhao, Yvonne Ngalame, Monica C Panelli, Dirk Nagorsen, Vladia Monsurró, Kina Smith, Nan Hu, Hua Su, Phil R Taylor, Francesco M Marincola, Ena Wang.
Abstract
BACKGROUND: Endogenous reference genes are commonly used to normalize expression levels of other genes with the assumption that the expression of the former is constant in different tissues and in different physiopathological conditions. Whether this assumption is correct it is, however, still matter of debate. In this study, we searched for stably expressed genes in 384 cDNA array hybridization experiments encompassing different tissues and cell lines.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15310404 PMCID: PMC516027 DOI: 10.1186/1471-2164-5-55
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
| cDNA FLJ40458 | 1571492 | Hs.181346 | 2835 | 0.19 | 0.27 | 0.39 | 0.15 |
| Unknown | 301067 | 2571 | 0.1 | 0.27 | 0 | 0.21 | |
| KIAA1935 | 39938 | Hs.300776 | 2359 | 0.16 | 0.28 | 0.01 | 0.19 |
| ESTs | 49313 | Hs.395460 | 2079 | 0.15 | 0.28 | 0.08 | 0.03 |
| cDNA FLJ30539 fis | 49463 | Hs.21489 | 2561 | 0.09 | 0.28 | 0.17 | 0.13 |
| SDCCAG16 | 1576228 | Hs.271926 | 2111 | 0.11 | 0.29 | 0.28 | 0.14 |
| clone IMAGE:41799 | 278673 | Hs.271721 | 3132 | 0.16 | 0.3 | -0.04 | 0.1 |
| PSIP2 | 289945 | Hs.82110 | 2521 | -0.07 | 0.3 | -0.06 | 0.19 |
| ETV2 | 1468722 | Hs.194061 | 2646 | 0.09 | 0.31 | 0 | 0.28 |
| ESTs | 1571401 | Hs.126999 | 2659 | 0.05 | 0.31 | -0.04 | 0.08 |
| HIP2 | 486259 | Hs.155485 | 2511 | 0.11 | 0.31 | 0.12 | 0.25 |
| ACTR8 | 156363 | Hs.124219 | 2731 | 0.08 | 0.32 | 0.14 | 0.16 |
| KIAA0769 | 299128 | Hs.19056 | 2148 | 0.14 | 0.32 | 0.05 | 0.2 |
| CSNK1G2 | 346031 | Hs.181390 | 2320 | -0.03 | 0.32 | -0.24 | 0.28 |
| C14orf117 | 796100 | Hs.103189 | 2008 | 0.12 | 0.32 | -0.01 | 0.16 |
| ATP6IP2 | 825077 | Hs.183434 | 2159 | 0.02 | 0.32 | 0.28 | 0.32 |
| Unknown | 1292073 | 2745 | -0.13 | 0.33 | 0.05 | 0.28 | |
| ESTs | 22137 | Hs.187406 | 3133 | 0.07 | 0.33 | -0.01 | 0.21 |
| ESTs | 32782 | Hs.443140 | 2464 | -0.02 | 0.33 | 0.09 | 0.26 |
| L3MBTL | 43090 | Hs.300863 | 2581 | -0.08 | 0.33 | -0.41 | 0.31 |
| GNRH1 | 487071 | Hs.82963 | 3294 | 0.05 | 0.33 | 0.23 | 0.23 |
| clone 24629 mRNA | 746258 | Hs.142570 | 2645 | 0.05 | 0.33 | -0.21 | 0.14 |
| FLJ12998 | 826367 | Hs.343627 | 2267 | 0.14 | 0.33 | 0.03 | 0.3 |
| cDNA: FLJ23477 fis | 1492329 | Hs.145362 | 2142 | 0.09 | 0.34 | 0.35 | 0.34 |
| HOXC4 | 1756945 | Hs.50895 | 2581 | 0.03 | 0.34 | -0.02 | 0.22 |
| WSX1 | 1855887 | Hs.132781 | 3259 | -0.01 | 0.34 | 0.12 | 0.3 |
| TFAP2B | 363144 | Hs.33102 | 2510 | 0.05 | 0.34 | 0.67 | 0.35 |
| TRIM31 | 509760 | Hs.91096 | 2753 | 0.06 | 0.34 | -0.08 | 0.2 |
| FLJ00166 | 713191 | Hs.43213 | 3134 | 0.08 | 0.34 | 0 | 0.22 |
| PPP3CA | 796730 | Hs.272458 | 2605 | -0.07 | 0.34 | -0.36 | 0.16 |
| PMS2L4 | 161373 | Hs.278468 | 2534 | -0.14 | 0.35 | -0.21 | 0.22 |
| DLGAP1 | 1758491 | Hs.75814 | 2143 | 0.02 | 0.35 | -0.24 | 0.2 |
| ESTs | 177884 | Hs.14613 | 2054 | 0.01 | 0.35 | -0.22 | 0.25 |
| NRL | 2364249 | Hs.89606 | 2300 | -0.04 | 0.35 | -0.09 | 0.14 |
| RAB36 | 281489 | Hs.38772 | 3143 | -0.08 | 0.35 | 0 | 0.12 |
| RPC8 | 323603 | Hs.353192 | 2367 | -0.06 | 0.35 | -0.33 | 0.24 |
| ZNF177 | 33294 | Hs.172979 | 2988 | 0.01 | 0.35 | -0.21 | 0.25 |
| LY6G5C | 448136 | Hs.246845 | 3591 | -0.02 | 0.35 | -0.44 | 0.28 |
| RAD17 | 586844 | Hs.16184 | 3797 | -0.01 | 0.35 | 0.12 | 0.15 |
| LOC253039 | 1033388 | Hs.41181 | 3612 | -0.02 | 0.36 | 0.31 | 0.08 |
| IMPDH2 | 1582050 | Hs.75432 | 2709 | -0.01 | 0.36 | -0.08 | 0.18 |
| PRMT3 | 2074202 | Hs.152337 | 2042 | 0.07 | 0.36 | -0.06 | 0.21 |
| AP3B2 | 47510 | Hs.21022 | 2350 | 0.03 | 0.36 | -0.23 | 0.31 |
| NF2 | 769716 | Hs.902 | 2887 | -0.08 | 0.36 | -0.11 | 0.31 |
| SCP2 | 855395 | Hs.75760 | 3218 | -0.12 | 0.36 | -0.1 | 0.19 |
| AKAP4 | 1643144 | Hs.97633 | 2557 | -0.03 | 0.37 | -0.07 | 0.15 |
| Unknown | 1671546 | 3386 | 0.03 | 0.37 | 1 | 0.42 | |
| TCF8 | 178463 | Hs.232068 | 2726 | -0.04 | 0.37 | -0.01 | 0.06 |
| TNP2 | 1839038 | Hs.2748 | 2737 | 0.08 | 0.37 | 0.11 | 0.24 |
| PIWIL1 | 2329739 | Hs.194712 | 2573 | -0.08 | 0.37 | -0.14 | 0.22 |
| DBCCR1 | 47037 | Hs.6090 | 2481 | -0.01 | 0.37 | -0.18 | 0.24 |
| SLC21A3 | 289706 | Hs.46440 | 2708 | 0 | 0.38 | -0.11 | 0.27 |
| ESTs | 35105 | Hs.403854 | 3126 | 0.03 | 0.38 | 0.23 | 0.18 |
| cDNA FLJ34400 fis | 511835 | Hs.380035 | 3058 | 0 | 0.38 | 0.02 | 0.37 |
| CNTN1 | 51640 | Hs.143434 | 2479 | -0.05 | 0.38 | -0.11 | 0.3 |
| TFCP2 | 843067 | Hs.154970 | 3728 | -0.06 | 0.38 | 0.16 | 0.34 |
| C17orf35 | 510032 | Hs.15196 | 2778 | -0.02 | 0.39 | 0.09 | 0.28 |
| MTP | 731054 | Hs.195799 | 2764 | -0.01 | 0.42 | -0.09 | 0.4 |
| NKTR | 712460 | NK-tumor recognition protein=cy | 7319.55 | 0.62 | 0.79 | 0.52 |
| NKTR | 712460 | NK-tumor recognition protein=cy | 3048.28 | |||
| NKTR | 712460 | NK-tumor recognition protein=cy | 8637.15 | 0.99 | 0.99 | 0.53 |
| NKTR | 2064497 | natural killer-tumor recognitio | 959.97 | 0.72 | 0.85 | 0.7 |
| PPIC | 882459 | peptidylprolyl isomerase C (cyc | 5034.82 | 2.11 | 1.45 | 0.44 |
| PPIB | 756600 | peptidylprolyl isomerase B (cyc | 6606.09 | 1.08 | 1.04 | 0.39 |
| PPIL2 | 450661 | peptidylprolyl isomerase (cyclo | 3035.17 | |||
| PPIL2 | 2017652 | peptidylprolyl isomerase (cyclo | 850.93 | |||
| PPIG | 809621 | peptidyl-prolyl isomerase G (cy | 3991.93 | 0.28 | 0.53 | 0.67 |
| PPID | 884500 | peptidylprolyl isomerase D (cyc | 5805.51 | 0.33 | 0.57 | 0.66 |
| PPID | 71154 | peptidylprolyl isomerase D (cyc | 5652.12 | 0.27 | 0.52 | 0.63 |
| PPIH | 767277 | peptidyl prolyl isomerase H (cy | 3277.26 | 0.28 | 0.53 | 0.73 |
| PPIF | 758343 | peptidylprolyl isomerase F (cyc | 15900.53 | 3.18 | 1.78 | 0.13 |
| CYP2J2 | 454580 | cytochrome P450, family 2, subf | 2302.76 | 0.71 | 0.84 | 0.65 |
| PPIA | 2580290 | peptidylprolyl isomerase A (cyc | 25478.36 | 1.32 | 1.15 | 0.36 |
| PPIA | 1570861 | peptidylprolyl isomerase A (cyc | 5028.34 | 0.76 | 0.87 | 0.46 |
| GAPD | 50117 | glyceraldehyde-3-phosphate dehy | 38011.52 | 1.66 | 1.29 | 0.4 |
| GAPD | 530934 | glyceraldehyde-3-phosphate dehy | 10526.82 | 1.14 | 1.07 | 0.37 |
| GAPD | 530868 | glyceraldehyde-3-phosphate dehy | 5052.59 | 0.81 | 0.9 | 0.25 |
| GAPD | 755641 | glyceraldehyde-3-phosphate dehy | 1693.23 | |||
| PGK1 | 949939 | Phosphoglycerate kinase 1 | 4452.92 | 0.4 | 0.85 | |
| B2M | 878798 | beta-2-microglobulin | 34211.05 | 2.08 | 1.44 | 0.43 |
| AMBP | 2063390 | alpha-1-microglobulin/bikunin p | 1813.96 | 0.39 | 0.86 | |
| GUSB | 2273001 | glucuronidase, beta | 6205.14 | 0.81 | 0.9 | 0.41 |
| GUSB | 276449 | glucuronidase, beta | 2241.73 | |||
| HPRT1 | 280507 | hypoxanthine phosphoribosyltran | 12778.31 | 1.29 | 1.14 | 0.35 |
| TBP | 280735 | TFIID=TATA box binding protein | 4065.4 | 0.49 | 0.73 | |
| TFR2 | 461750 | transferrin receptor 2 | 2700.22 | |||
| TFR2 | 2408681 | transferrin receptor 2 | 2958.88 |
Figure 1Comparison of gp100 expression normalized by different endogenous reference genes. Candidate endogenous reference genes were selected among those in Table 1. The gp100 probe (Cy3) was co-hybridized with one endogenous reference gene probe (Cy5) at the time to the transcriptome array. The transcriptome array included 235 cDNA libraries derived from samples of melanocytic lineage (maroon bar) and 594 cDNA libraries from samples of non melanocytic lineage (green bar). Melanocytic samples consisting in the overwhelming majority of melanoma metastases or melanoma cell lines while non-melanocytic libraries included a large collection of esophageal, kidney, colon and other cancers and several normal tissues or circulating mononuclear cells. The complete list of samples is available upon request. The expression of gp100 normalized with different endogenous reference genes was compared by unpaired two-tailed student t test and the endogenous reference genes were ranked according to the level of significance in their ability to discriminate between melanocytic and non-melanocytic lesions (data presented as the Log10 p2-value (shown in the boxes associated with individual graphs; for details see Figure 2). The distribution of the Log2 ratios for each individual cDNA library is shown for each gp100 / endogenous reference gene combination. In addition, results compiled using the average of the Log2 ratios for all the endogenous reference genes, the 5 and the 3 with the lowest p2-value are presented (orange bar graphs).
Figure 2Expression of gp100 by melanocytic and non melanocytic lesions normalized with different endogenous reference genes. Average gp100 / endogenous reference gene Log2 ratios for melanocytic and non-melanocytic lesions are shown together with the standard deviation (SD) standard error from the mean (SEM) and the Log10 of the t-test p2-values when melanocytic and non-melanocytic lesions were compared. Also data derived from mathematically averaging the results obtained with all the endogenous reference genes, the ones yielding the best 5 individual p2-values and the best three are shown. The same data are presented visually in the bar graph below; in black are data derived with individual endogenous reference gene normalizations, in orange data derived by averaging results from different endogenous reference genes. Filled bares portrait data from melanocytic lesions, empty bars from non-melanocytic lesions.
Figure 3Relative expression of gp100, Rho-C and DICE in melanocytic and non-melanocytic samples. Test samples (Cy3) and endogenous reference genes (Cy5) were hybridized to the transcriptome array as described in Figure 1. Test gene / endogenous reference gene Log2 ratios are displayed as a bar graph for NEED8, β-actin and for the averages of test / endogenous reference geneLog2 ratios when the three endogenous reference genes with the best discriminating power in separating gp100 expression between melanocytic (maroon bar) and non-melanocytic (green bar) lesions (NEDD8, RAB3 and FZD6) were used. Samples derived from melanoma metastases are shown by the orange bar. In the boxes the Log10 p2-value of significance of differences between relevant samples (se text) are shown; ns = non significant).
Figure 4Correlation of gp100 expression estimated obtained by intracellular FACS analysis and by gene profiling with the transcriptome array. Cell lines with different level of gp100 expression by intra-cellular FACS analysis using the gp100-specific mAb HMB45 [35] were used for the analysis. The compiled information from the transcriptome array in which cDNAs from each cell line was spotted are shown. The Cy5/Cy3 (endogenous reference gene / gp100) Log2 ratios are shown for each endogenous reference gene evaluated. In addition, ratios derived by using the data from all the endogenous reference genes, the best 5 and best 3 according to figure 2 are also presented. Pearson's correlation for the data set is shown for each endogenous reference gene and the same information is summarized graphically at the bottom of the figure. MEF = mean equivalent of fluorescence [35].
Figure 5Absolute and normalized expression of gp100 based on qRT-PCR. Four melanoma cell lines expressing gp100 (MEL-553B, MEL 1317, MEL 526 and MEL-1102) and 2 not expressing gp100 (MEL-836 and MEL-1195) protein by FACS analysis [35] (maroon horizontal bar) were tested for gp100 expression by qRT-PCR as previously described [40]. In addition four fine need aspirates of melanoma metastases all expressing GP100 by immunohistochemistry (orange horizontal bars) and two renal cell, two esophageal and one gastric cancer specimens all not expressing gp100 (green horizontal bar) were tested. Similarly the gp100 not expressing HeLa cell line was tested. Absolute gp100 copy number is shown in (a); normalized expression of gp100 is shown using the average of all endogenous reference gene results (b). The protein expression for the melanoma cell lines is presented as mean equivalent of fluorescence (MEF) [35] as well as immunohistochemical evaluation while the expression by FNA is shown in (c) based on immunohistochemical (HIC) evaluation as previously described [46]. Absolute copy numbers of gp100 estimated by qRT-PCR are also shown.
Quantitative RT-PCR primers and probes
| AFAP | (+)-TGTCAAGTTAAACCACTAATGTGTTGGT | |
| (-)-GGCATCCAAATTCTCCAAGAAA | ||
| FAM-TGCTGCCTCTCCTGAGTAGGGTGGGT-TAMRA | ||
| CDK5R1 | (+)-TCCTACATGGGCAACGAGATC | |
| (-)-CCAAAAGGCCTCCTTGCA | ||
| FAM -TACCCGCTCAAGCCCTTCCTGGTG -TAMRA | ||
| COL8A1 | (+)-CCGAGCTAACCGCACCTTT | |
| (-)-GTCTGCGGGTTGTAGTTCTGTCT | ||
| FAM -AGTGAAGTTTAACAAACTGCTGTATAACGG -TAMRA | ||
| FZD | (+)-AGCCTCAAAGGTTCCACATCTC | |
| (-)-AGGTCACTTCCAGTGTAACACAAATT | ||
| FAM -TGAGAAAAGAGCAGGGAGGTGGTTGTCA -TAMRA | ||
| GPLD1-1 | (+)-CAGATTGAAGATTTCACTGCATTTC | |
| (-)-CATCAAAATGCTCACCATGGA | ||
| FAM -TCTGCCCACCTCTCTCATGCTGAATCAC -TAMRA | ||
| GPLD1-2 | (+)-CTTTTGCCTGTAGTAGTAAATTGCTTTTA | |
| (-)-AACTGGCCATATAAC CAAAGGTGTT | ||
| FAM -TGAATGGTGTTTATTAAACCCTTATGGTCGATATTTCC-TAMRA | ||
| HIRIP5 | (+)-GCTGCCCTAGTTCAATCATTACTCT | |
| (-)-CGCCTTCTACCTCCGGAATAT | ||
| FAM – AAAAATGGAATTCAGAACATGCTGCA-TAMRA | ||
| HIST1HIA | (+)-AGGCGTCCTCCGTGGAA | |
| (-)-ATGCACCCGTTGCCTTAGTT | ||
| FAM – AGCCCGGCGCCTCAAAGGTG-TAMRA | ||
| NEDD8 | (+)-TGACCGGAAAGGAGATTGAGA | |
| (-)-CCACACGCTCCTTGATTCG | ||
| FAM – TGACATTGAACCTACAGACAAGGTGGA-TAMRA | ||
| PTH | (+)-GCATAACCTGGGAAAACATCTGA | |
| (-)-TGCACATCCTGCAGCTTCTT | ||
| FAM -TCGATGGAGAGAGTAGAATGGCTGC-TAMRA | ||
| RAB31 | (+)-CCCCTGAAGGATGCTAAGGAA | |
| (-)-AGCATTTTTTGCACTTGTCTCAAC | ||
| FAM – ACGCTGAATCCATAGGTGCCATC-TAMRA | ||
| SNRPD3 | (+)-GGCACAGCTGGAGCAGGTAT | |
| (-)-CTTCAGCATGTCAGGCAAAATC | ||
| FAM – ATCCGTGGCAGCAAAATCCGC -TAMRA | ||
| β-actin | (+)-GGCACCCAGCACAATGAAG | |
| (-)-GCCGATCCACACGGAGTACT | ||
| FAM-TCAAGATCATTGCTCCTCCTGAGCGC-TAMRA | ||
| gp100 | (+)GGTTCCTTTTCCGTCACCCT | |
| (-)CTCACCGGACGGCACAG | ||
| FAM-ACATTGTCCAGGGTATTGAAAGTGCCGAGAT-TAMRA |